Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial

Background/Aims: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication. Methods: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninf...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Yoon Jin Choi, Yong Chan Lee, Jung Mogg Kim, Jin Il Kim, Jeong Seop Moon, Yun Jeong Lim, Gwang Ho Baik, Byoung Kwan Son, Hang Lak Lee, Kyoung Oh Kim, Nayoung Kim, Kwang Hyun Ko, Hye-Kyung Jung, Ki-Nam Shim, Hoon Jai Chun, Byung-Wook Kim, Hyuk Lee, Jie-Hyun Kim, Hyunsoo Chung, Sang Gyun Kim, Jae Young Jang
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Gastroenterology Council for Gut and Liver 2022-07-01
Serie:	Gut and Liver
Soggetti:	helicobacter pylori potassium-competitive acid blocker tegoprazan
Accesso online:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl220055
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!